|
| 36179280 | The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. | Blood | 2023 |
| 37277510 | Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ. | Commun Biol | 2023 |
| 35344582 | Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. | Blood | 2022 |
| 34725211 | BT7480, a novel fully synthetic <i>Bicycle</i> tumor-targeted immune cell agonistâ¿¢ (<i>Bicycle</i> TICAâ¿¢) induces tumor localized CD137 agonism. | J Immunother Cancer | 2021 |
| 33538798 | Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. | Blood | 2021 |
| 33580200 | The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. | Leukemia | 2021 |
| 34555678 | Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis. | J Autoimmun | 2021 |
| 32824276 | Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2. | Cancers (Basel) | 2020 |
| 32015491 | Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. | Leukemia | 2020 |
| 30642912 | Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy. | Clin Cancer Res | 2019 |
| 31434681 | Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. | Blood Adv | 2019 |
| 29650362 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. | Lancet Oncol | 2018 |
| 29724899 | The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. | Blood | 2018 |
| 27773930 | Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial. | Leukemia | 2017 |
| 28428443 | Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in <i>MLL</i>-Rearranged Leukemia. | Mol Cancer Ther | 2017 |
| 27843137 | PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. | Leukemia | 2017 |
| 27783255 | Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). | Invest New Drugs | 2017 |
| 27890934 | EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. | Leukemia | 2017 |
| 26184912 | BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma. | Cell Death Differ | 2016 |
| 26488112 | The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. | Leukemia | 2016 |
| 26675346 | Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. | Blood | 2016 |
| 27282254 | Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. | Leukemia | 2016 |
| 26957556 | Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. | Clin Cancer Res | 2016 |
| 25733005 | Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. | Br J Haematol | 2015 |
| 24232190 | Applications of pathology-assisted image analysis of immunohistochemistry-based biomarkers in oncology. | Vet Pathol | 2014 |
| 24335104 | Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. | Blood | 2014 |
| 23633453 | Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. | Clin Cancer Res | 2013 |
| 20604938 | Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. | BMC Genomics | 2010 |